Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Impact of surgical optimality on the survival for patients diagnosed with clear cell carcinoma of ovary: a propensity score analysis with long-term follow-up
C.H. Lu1, 2, 3, 4, Y.H. Chang4, 5, C.R. Lai6, W.H. Lee4, 5, Y. Chang4, 5, C.M. Chuang4, 5, 7*
1 Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan
2 Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan
3 Rong-Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan
4 Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
5 Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan
6 Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan
7 Department of National Taipei University of Nursing and Health Sciences, Taipei, Taiwan
Eur. J. Gynaecol. Oncol. 2018, 39(2), 180–186; https://doi.org/10.12892/ejgo3650.2018
Published: 10 April 2018
Purpose of Investigation: The authors aimed to investigate the impact of surgical optimality on clear cell carcinoma (CCC) versus serous adenocarcinoma of ovary (SAC). Materials and Methods: A retrospective analysis of a prospectively collected healthcare database in a single institution, recruiting consecutive patients diagnosed with Stage III epithelial ovarian cancer between January 2001 and December 2010, was conducted. Results: For optimal disease, median overall survival (95% confidence interval) was 57.1 (42.5-78.6) months for SAC and 52.6 (35.3-61.1) months for CCC, respectively (hazard ratio = 1.28, p = 0.222). For suboptimal disease, the corresponding value was 43.3 (36.5-58.2) months for SAC and 24.6 (21.9-37.1) months for CCC, respectively (hazard ratio = 2.33, p < 0.001). Conclusion: For optimal residual disease, CCC shows equal survival to SAC, while for suboptimal residual disease, CCC still shows very dismal outcome compared to SAC, suggesting the urgent need to test novel drugs to treat this subset of patients.
Clear cell carcinoma